GO
Loading...

AstraZeneca PLC

More

  • Nov 20- A U.S. court has denied a request by Indian drugmaker Ranbaxy Laboratories Ltd to stop competitors from launching copies of AstraZeneca Plc's heartburn pill Nexium and Roche's antiviral, a court filing showed. Ranbaxy had filed a lawsuit against the U.S. Food and Drug Administration last week for revoking tentative approvals it gave the company to make...

  • Nov 20- A U.S. court has denied a request by Indian drugmaker Ranbaxy Laboratories Ltd to stop competitors from launching copies of AstraZeneca Plc's heartburn pill Nexium and Roche's antiviral Valcyte, a court filing showed. Ranbaxy had sought the restraining order against Dr Reddy's Laboratories and U.S. firm Endo International Plc in a lawsuit it filed...

  • European shares erase gains ahead of Fed minutes Wednesday, 19 Nov 2014 | 12:35 PM ET

    LONDON, Nov 19- European shares ended flat after hitting a seven-week high earlier on Wednesday, with investors trading cautiously ahead of minutes from the most recent Federal Reserve policy meeting. The market also faced pressure from a sharp decline in mining shares after China's iron ore futures dropped nearly 5 percent to a record low.

  • European shares edge lower ahead of Fed minutes Wednesday, 19 Nov 2014 | 11:24 AM ET

    LONDON, Nov 19- European shares edged lower from a seven-week high late on Wednesday, tracking a fall in U.S. equities, with investors trading cautiously ahead of minutes from the most recent Federal Reserve policy meeting. The market also came under pressure from a sharp decline in mining shares after China's iron ore futures dropped nearly 5 percent to a record...

  • European shares advance, Swiss index hits 9,000 Wednesday, 19 Nov 2014 | 8:48 AM ET

    LONDON, Nov 19- The pan-European FTSEurofirst 300 share index climbed to a seven-week high on Wednesday, helped by broker upgrades, and Switzerland's SMI equity index hit the 9,000 mark for the first time since late 2007.. Prudential rose 1.3 percent after Deutsche Bank increased its target price for the stock to 1,680 pence from 1,630 pence, Severn Trent was up...

  • European shares edge higher, Swiss index hits 7-year high Wednesday, 19 Nov 2014 | 6:09 AM ET

    LONDON, Nov 19- European shares turned positive in morning trading on Wednesday, helped by some encouraging broker upgrades, with Switzerland's SMI equity index hitting the 9,000- point mark for the first time since late 2007.. Prudential rose 1.1 percent to lead insurers after Deutsche Bank increased its target price for the stock to 1,680 pence from 1,630...

  • Midday movers: Allergan, Apple, Fluor & more Tuesday, 18 Nov 2014 | 12:56 PM ET

    Some of Tuesday midday movers:

  • *AstraZeneca designates oncology as new growth driver. LONDON, Nov 18- AstraZeneca touted an "industry-leading" line-up of hot new cancer drugs on Tuesday, aiming to show investors it has a strong independent future just days before takeover rules would allow Pfizer to launch a new bid. AstraZeneca, which saw off a $118 billion approach from Pfizer in May, is his...

  • *AstraZeneca designates oncology as new growth driver. LONDON, Nov 18- AstraZeneca touted an "industry-leading" line-up of hot new cancer drugs at an investor day on Tuesday, aiming to show it has a strong independent future after seeing off a $118 billion bid from Pfizer in May. AstraZeneca is his biggest holding.

  • AstraZeneca trumpets strength in drug development Tuesday, 18 Nov 2014 | 3:24 AM ET
    British pharmaceutical company AstraZeneca's manufacturing site in Macclesfield, northwest England.

    AstraZeneca said it had made good progress in developing a pipeline of new drugs.

  • *Investor day comes 8 days before Pfizer can resume pursuit. LONDON, Nov 18- AstraZeneca, determined to show it has a strong independent future after seeing off a $118 billion bid from Pfizer in May, said it had made good progress in developing a pipeline of new drugs. It reiterated it was on course to return to growth and that annual sales would rise by three quarters...

  • AstraZeneca trumpets progress in cancer, other drugs Tuesday, 18 Nov 2014 | 2:20 AM ET

    LONDON, Nov 18- AstraZeneca, determined to show it has a strong independent future after seeing off a $118 billion bid from Pfizer in May, said it had made good progress in developing a pipeline of new drugs. AstraZeneca executives will present further details at a six-hour investor meeting later on Tuesday. The event comes just eight days before British takeover...

  • Early Movers: BHI, HAL, TSN, AGN, GM, MAR & more Monday, 17 Nov 2014 | 8:14 AM ET

    Some of the names on the move ahead of the open.

  • LONDON, Nov 17- An experimental lupus drug from AstraZeneca significantly improved the symptoms of lupus in a mid-stage clinical trial, boosting prospects for a medicine the company believes could become a major seller. AstraZeneca's sifalimumab works in a different way to Benlysta by targeting interferon, a protein involved in inflammation.

  • German Merck, Pfizer in immunotherapy deal Monday, 17 Nov 2014 | 5:47 AM ET

    Germany's Merck KGaA said Monday it struck an alliance over cancer immunotherapy drugs with Pfizer, triggering an upfront payment of $850 million by the U.S. drugmaker.

  • *Deal may reduce need for Pfizer to acquire AstraZeneca. FRANKFURT/ LONDON, Nov 17- Pfizer punctured investor expectations of a renewed bid for AstraZeneca on Monday by signing a major cancer drug deal with Germany's Merck KGaA, reducing the U.S. firm's need for Astra's products. Winning access to AstraZeneca's cancer pipeline has been viewed as a key goal for...

  • Nov 16- Chemotherapy as a treatment for advanced melanoma could soon become obsolete, researchers said on Sunday, after patients taking an experimental immuno-oncology drug from Bristol-Myers Squibb Co had a much higher survival rate and had other favorable results. Georgina Long, an associate professor at the Melanoma Institute Australia who helped lead...

  • LONDON, Nov 14- Pfizer appears unlikely to make a fresh bid for AstraZeneca in 12 days time, when an enforced cooling-off period ends, and the U.S. drugmaker is now weighing other less risky targets. People with direct knowledge of the situation said Pfizer has been reviewing different takeover scenarios with a U.S. investment bank ahead of Nov. 26, when it is allowed...

  • But a series of failed deals, including the collapse of a $55 billion tie-up between UK drugmaker Shire and U.S. peer AbbVie, has led to losses for some of the world's biggest proponents of the strategy, with investors pulling out $3.3 billion in the last two months alone. "The AbbVie/ Shire break, in particular, has led to a far reaching de-risking exercise for many...

  • LONDON, Nov 13- AstraZeneca is developing an antibody treatment to reverse the blood-thinning effect of its heart drug Brilinta in rare emergency situations, such as urgent surgery or in the event of major bleeding. AstraZeneca said on Thursday the experimental antibody product, MEDI2452, was in pre-clinical tests at its MedImmune biotech unit.